MicroRNA 1296 (miR-1296)

MicroRNA 1296 (miR-1296) is a small endogenous non-coding RNA that regulates gene expression by binding to complementary sequences on mRNA transcripts, leading to their degradation or translational repression[2][3]. MiR-1296 is implicated in multiple aspects of cancer biology, including cell proliferation, migration, invasion, and apoptosis. Its function is context-dependent: in several cancers, it acts as a tumor suppressor (downregulated, loss associated with poor outcomes and enhanced tumor growth), while in colorectal cancer, it may act as an oncogenic miRNA (upregulated with recurrence and poor prognosis)[1][2][3]. Its principal mechanisms involve post-transcriptional repression of oncogenes such as ABL2, Cyclin D1, ERBB2, and SFPQ, and inhibition of cancer-promoting pathways like Wnt signaling and PI3K/AKT[1][2][3]. \nMiR-1296 is considered a potential therapeutic target and biomarker in oncology due to its functional significance and disease associations. There are currently no approved drugs directly targeting miR-1296; research into miRNA-based therapies is ongoing. Its modulation may present safety concerns typical of nucleic acid therapeutics, such as off-target gene regulation. Development as a biomarker and therapeutic target is actively under investigation, especially in lung, glioma, breast, gastric, hepatic, prostate, and colorectal cancers[1][2][3].

Other names

hsa-mir-1296MIR1296MIRN1296mir-1296

For potential therapeutics: Synthetic miR-1296 mimics (to increase its function) or miR-1296 inhibitors (to decrease its function). Mechanisms involve modulation of tumor cell proliferation and apoptosis by targeting specific oncogenic pathways (Wnt signaling, PI3K/AKT, ERBB2/Rac1, Cyclin D1, etc.). Direct targeting of mRNA through complementary seed region interactions.